Develops and sells prescription medicines and vaccines, rebuilding its pipeline through acquisitions after an extraordinary pandemic revenue cycle.
Pfizer (PFE) scores 3.2 out of 10 as of September 13, 2026, computed from its reported financial statements. That reads as low quality. The reading rests on efficiency, and growth is what holds it back.
One pillar, solvency, is unscored because the filings behind it carry too little to judge. It is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
Few large companies have had their revenue base move as violently in as short a time, which punishes predictability and growth in a way that reflects real history rather than a flaw in the measurement. Solvency also carries the debt raised to fund the rebuild. A quality score here is really a question about which base you believe is the normal one.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Pfizer scores 3.2 out of 10, which reads as low quality. Its strongest pillar is efficiency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
It was last recomputed on September 13, 2026. The score moves with the financial statements, i.e. quarterly, so this page changes when a new filing changes the answer rather than on a schedule. Live figures for PFE are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card